Allakos Inc. Logo

Allakos Inc.

ALLK

(1.2)
Stock Price

1,16 USD

-131.66% ROA

-142.6% ROE

-0.28x PER

Market Cap.

57.761.840,00 USD

47.3% DER

0% Yield

-1915.2% NPM

Allakos Inc. Stock Analysis

Allakos Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Allakos Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.64x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (17%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-48.7%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-45.39%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Allakos Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Allakos Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Allakos Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Allakos Inc. Revenue
Year Revenue Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Allakos Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 14.672.000
2017 18.506.000 20.72%
2018 33.287.000 44.4%
2019 61.858.000 46.19%
2020 105.533.000 41.39%
2021 196.328.000 46.25%
2022 265.081.000 25.94%
2023 146.996.000 -80.33%
2023 150.908.000 2.59%
2024 74.196.000 -103.39%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Allakos Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 2.388.000
2017 3.748.000 36.29%
2018 12.434.000 69.86%
2019 29.560.000 57.94%
2020 51.524.000 42.63%
2021 75.147.000 31.44%
2022 57.348.000 -31.04%
2023 45.844.000 -25.09%
2023 45.148.000 -1.54%
2024 36.844.000 -22.54%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Allakos Inc. EBITDA
Year EBITDA Growth
2016 -16.912.000
2017 -22.013.000 23.17%
2018 -45.721.000 51.85%
2019 -91.418.000 49.99%
2020 -157.057.000 41.79%
2021 -271.475.000 42.15%
2022 -322.429.000 15.8%
2023 -186.644.000 -72.75%
2023 -189.915.000 1.72%
2024 -111.040.000 -71.03%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Allakos Inc. Gross Profit
Year Gross Profit Growth
2016 -148.000
2017 -241.000 38.59%
2018 -242.000 0.41%
2019 -1.508.000 83.95%
2020 -2.339.000 35.53%
2021 -4.880.000 52.07%
2022 -9.975.000 51.08%
2023 0 0%
2023 -6.141.000 100%
2024 -3.492.000 -75.86%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Allakos Inc. Net Profit
Year Net Profit Growth
2016 -17.100.000
2017 -23.552.000 27.39%
2018 -43.538.000 45.9%
2019 -77.663.000 43.94%
2020 -147.622.000 47.39%
2021 -267.173.000 44.75%
2022 -317.475.000 15.84%
2023 -182.504.000 -73.96%
2023 -185.701.000 1.72%
2024 -106.704.000 -74.03%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Allakos Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 -1
2017 -1 0%
2018 -2 100%
2019 -2 -100%
2020 -3 50%
2021 -5 50%
2022 -5 20%
2023 -2 -150%
2023 -2 0%
2024 -1 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Allakos Inc. Free Cashflow
Year Free Cashflow Growth
2016 -17.812.000
2017 -22.832.000 21.99%
2018 -45.396.000 49.7%
2019 -63.782.000 28.83%
2020 -114.554.000 44.32%
2021 -241.074.000 52.48%
2022 -288.304.000 16.38%
2023 -29.586.000 -874.46%
2023 -117.072.000 74.73%
2024 -16.963.000 -590.16%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Allakos Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -17.578.000
2017 -22.568.000 22.11%
2018 -38.450.000 41.31%
2019 -63.012.000 38.98%
2020 -113.924.000 44.69%
2021 -207.853.000 45.19%
2022 -279.971.000 25.76%
2023 -29.479.000 -849.73%
2023 -116.480.000 74.69%
2024 -16.921.000 -588.38%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Allakos Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 234.000
2017 264.000 11.36%
2018 6.946.000 96.2%
2019 770.000 -802.08%
2020 630.000 -22.22%
2021 33.221.000 98.1%
2022 8.333.000 -298.67%
2023 107.000 -7687.85%
2023 592.000 81.93%
2024 42.000 -1309.52%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Allakos Inc. Equity
Year Equity Growth
2016 -36.436.000
2017 -58.768.000 38%
2018 183.994.000 131.94%
2019 495.721.000 62.88%
2020 654.395.000 24.25%
2021 445.476.000 -46.9%
2022 310.433.000 -43.5%
2023 221.043.000 -40.44%
2023 168.817.000 -30.94%
2024 83.999.000 -100.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Allakos Inc. Assets
Year Assets Growth
2016 14.176.000
2017 87.029.000 83.71%
2018 191.259.000 54.5%
2019 516.894.000 63%
2020 719.618.000 28.17%
2021 534.824.000 -34.55%
2022 386.420.000 -38.4%
2023 283.495.000 -36.31%
2023 243.610.000 -16.37%
2024 156.458.000 -55.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Allakos Inc. Liabilities
Year Liabilities Growth
2016 50.612.000
2017 145.797.000 65.29%
2018 7.265.000 -1906.84%
2019 21.173.000 65.69%
2020 65.223.000 67.54%
2021 89.348.000 27%
2022 75.987.000 -17.58%
2023 62.452.000 -21.67%
2023 74.793.000 16.5%
2024 72.459.000 -3.22%

Allakos Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.12
Net Income per Share
-2.32
Price to Earning Ratio
-0.28x
Price To Sales Ratio
5.37x
POCF Ratio
-0.56
PFCF Ratio
-0.56
Price to Book Ratio
0.69
EV to Sales
6.6
EV Over EBITDA
-0.39
EV to Operating CashFlow
-0.69
EV to FreeCashFlow
-0.69
Earnings Yield
-3.57
FreeCashFlow Yield
-1.79
Market Cap
0,06 Bil.
Enterprise Value
0,07 Bil.
Graham Number
7.04
Graham NetNet
0.57

Income Statement Metrics

Net Income per Share
-2.32
Income Quality
0.5
ROE
-1.43
Return On Assets
-1.32
Return On Capital Employed
-1.56
Net Income per EBT
1
EBT Per Ebit
1.1
Ebit per Revenue
-17.44
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
3.97
Research & Developement to Revenue
13.14
Stock Based Compensation to Revenue
3.13
Gross Profit Margin
0.53
Operating Profit Margin
-17.44
Pretax Profit Margin
-19.15
Net Profit Margin
-19.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.16
Free CashFlow per Share
-1.17
Capex to Operating CashFlow
-0
Capex to Revenue
0.01
Capex to Depreciation
0.02
Return on Invested Capital
-1.55
Return on Tangible Assets
-1.32
Days Sales Outstanding
0
Days Payables Outstanding
1167.12
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.31
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,39
Book Value per Share
0,95
Tangible Book Value per Share
0.95
Shareholders Equity per Share
0.95
Interest Debt per Share
0.48
Debt to Equity
0.47
Debt to Assets
0.25
Net Debt to EBITDA
-0.07
Current Ratio
3.57
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
118864000
Working Capital
0,09 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,02 Bil.
Average Inventory
0
Debt to Market Cap
0.69

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Allakos Inc. Dividends
Year Dividends Growth

Allakos Inc. Profile

About Allakos Inc.

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

CEO
Dr. Robert Alexander Ph.D.
Employee
131
Address
975 Island Drive
Redwood City, 94065

Allakos Inc. Executives & BODs

Allakos Inc. Executives & BODs
# Name Age
1 Dr. Robert Alexander Ph.D.
Chief Executive Officer & Director
70
2 Dr. Adam L. Tomasi Ph.D.
President
70
3 Mr. Baird Radford III
Chief Financial Officer
70
4 Dr. Chin Lee M.D., M.P.H.
Chief Medical Officer
70
5 Mr. Alan Chang
Director of Medical Affairs & Data Analytics
70
6 Ms. Mary Cromwell Ph.D.
Chief Technical Officer
70

Allakos Inc. Competitors